BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, ...
BeOne Medicines AG (formerly BeiGene, Ltd.) is a multinational oncology company founded in 2010 by John V. Oyler and Xiaodong Wang. Headquartered in Basel, Switzerland, with operations in the U.S., China, Europe, and internationally, it specializes in developing and commercializing cancer therapies. The company has a robust portfolio including commercial-stage products like BRUKINSA (a BTK inhibitor for blood cancers), TEVIMBRA (an anti-PD-1 antibody), SYLVANT (for Castleman disease), and others. Its clinical pipeline includes novel treatments such as Sonrotoclax (Bcl-2 inhibitor), BGB-16673 (BTK degrader), and multiple antibody-drug conjugates (ADCs). Collaborations with major pharma like Amgen, BMS, and Novartis enhance its capabilities. Financially, the company has shown profitability with a net margin of 8.9%, revenue per share of $51.99, and a strong balance sheet with cash per share of $43.72. It employs around 12,000 people as of recent data, with a market cap of approximately $35 billion. The company is driven by a mission to transform cancer care and expand patient access globally. Under CEO John V. Oyler, BeOne continues to invest heavily in R&D (about 37.7% of revenue) while achieving operational efficiency.
Catalent Pharma SolutionsDelisted (formerly NYSE:CTLT, acquired by Novo Holdings December 2024)Internal Manufacturing - Hopewell, NJInternal Manufacturing - Guangzhou, ChinaInternal Manufacturing - Suzhou, ChinaWuXi AppTec / Shanghai Syn-The-AllHKEx:2359Generic API ManufacturersExcipients and Raw Material SuppliersSingle-Use Bioprocessing Suppliers
